Ekso Bionics (NASDAQ:EKSO) Upgraded at StockNews.com

StockNews.com upgraded shares of Ekso Bionics (NASDAQ:EKSO) from a sell rating to a hold rating in a research report released on Saturday morning.

Separately, HC Wainwright cut their price objective on Ekso Bionics from $10.00 to $9.25 and set a buy rating for the company in a report on Tuesday, March 5th.

Ekso Bionics Stock Performance

EKSO opened at $1.47 on Friday. The firm has a market cap of $26.31 million, a PE ratio of -1.34 and a beta of 1.65. The company has a quick ratio of 1.87, a current ratio of 2.49 and a debt-to-equity ratio of 0.38. The business has a fifty day simple moving average of $1.90 and a 200-day simple moving average of $1.51. Ekso Bionics has a fifty-two week low of $0.62 and a fifty-two week high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Monday, March 4th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.11). The company had revenue of $4.85 million for the quarter, compared to the consensus estimate of $4.80 million. Ekso Bionics had a negative return on equity of 90.80% and a negative net margin of 83.14%. During the same period in the prior year, the business earned ($0.24) earnings per share. As a group, equities analysts predict that Ekso Bionics will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Ekso Bionics

Several institutional investors have recently bought and sold shares of EKSO. Kent Lake Capital LLC acquired a new position in shares of Ekso Bionics during the 4th quarter valued at about $353,000. Strategic Wealth Investment Group LLC lifted its holdings in Ekso Bionics by 21.8% in the 4th quarter. Strategic Wealth Investment Group LLC now owns 51,950 shares of the company’s stock worth $130,000 after purchasing an additional 9,285 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in Ekso Bionics in the 3rd quarter worth approximately $28,000. Finally, Renaissance Technologies LLC lifted its holdings in Ekso Bionics by 153.4% in the 2nd quarter. Renaissance Technologies LLC now owns 44,606 shares of the company’s stock worth $74,000 after purchasing an additional 27,006 shares during the last quarter. 9.54% of the stock is currently owned by institutional investors.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.